search
Back to results

Treatment of Bipolar Mania in Older Adults (GERI-BD)

Primary Purpose

Bipolar Disorder, Mania

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Lithium (LI)
Divalproex (DV)
Sponsored by
Weill Medical College of Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of DSM-IV Bipolar Disorder, Type I: current manic, mixed, or hypomanic episodes Exclusion Criteria: Rapid cycling bipolar disorder History of substance abuse or dependence within last 3 months Diagnosis of schizophrenia or other chronic psychotic conditions Acute or unstable medical illness Documented intolerance to Lithium, Depakote, Risperidone, or Lorazepam Dementia Inability to communicate in English

Sites / Locations

  • Precise Research Centers
  • Weill Cornell Medical College
  • Duke University Medical Center
  • University Hospitals Case Medical Center
  • University of Pennsylvania
  • University of Pittsburgh
  • Baylor College of Medicine
  • Centre for Addiction and Mental Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Lithium (LI)

Divalproex (DV)

Arm Description

Participants will receive 9 weeks of treatment with lithium

Participants will receive 9 weeks of treatment with divalproex

Outcomes

Primary Outcome Measures

Sedation Score
The Sedation Item score of the UKU (Norwegian for Committee of Clinical Investigations) Side Effect Rating Scale. A higher value indicates greater severity. Range is 0-3 (not present, mild, moderate, or severe).
Young Mania Rating Scale (YMRS) Scores
The Young Mania Rating Scale is an eleven item interviewer-rated instrument. Four items are scored 0-8, the others 0-4. The total score therefore ranges from 0-60, with higher values reflecting greater severity.

Secondary Outcome Measures

Full Information

First Posted
November 14, 2005
Last Updated
August 27, 2018
Sponsor
Weill Medical College of Cornell University
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00254488
Brief Title
Treatment of Bipolar Mania in Older Adults
Acronym
GERI-BD
Official Title
Acute Pharmacotherapy of Late-Life Mania (GERI-BD)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
November 2005 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will compare the benefits and side effects of lithium and divalproex in the treatment of older adults with bipolar mania.
Detailed Description
This is the first controlled acute treatment study of bipolar disorder in adults 60 years or older with current DSM-IV manic, mixed, or hypomanic episodes. The number of older adults with severe and disabling bipolar disorder is increasing, and information to guide the management of the treatment of the disease is lacking in this population. Guidelines for treatment of younger people with bipolar disorder cannot be used for older people, and there are no safety and efficacy data upon which to base initial treatment decisions for older patients with bipolar mania. Mood stabilizers (lithium and divalproex) are the first-line treatment for bipolar disorder. However, in aged patients physiological changes and comorbid diseases may increase vulnerability to side effects and limit the benefits of the medications. This double-blind study will compare the benefits and side-effects of 9 weeks of treatment with lithium and divalproex in people with bipolar mania. Participants, who may be treated during inpatient hospitalization or as outpatients, will be randomly assigned to receive either lithium or divalproex. During the first 3 weeks of treatment careful titration of lithium and divalproex will be done to reach dose ranges. All other psychotropic medications will be discontinued. Behavioral interventions and/or lorazepam may be added, if necessary. After the first 3 weeks, if symptoms do not improve, risperidone will be added to be taken everyday with the study medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder, Mania

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
224 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lithium (LI)
Arm Type
Experimental
Arm Description
Participants will receive 9 weeks of treatment with lithium
Arm Title
Divalproex (DV)
Arm Type
Experimental
Arm Description
Participants will receive 9 weeks of treatment with divalproex
Intervention Type
Drug
Intervention Name(s)
Lithium (LI)
Other Intervention Name(s)
Depakote
Intervention Description
The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
Intervention Type
Drug
Intervention Name(s)
Divalproex (DV)
Other Intervention Name(s)
Valproate
Intervention Description
Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
Primary Outcome Measure Information:
Title
Sedation Score
Description
The Sedation Item score of the UKU (Norwegian for Committee of Clinical Investigations) Side Effect Rating Scale. A higher value indicates greater severity. Range is 0-3 (not present, mild, moderate, or severe).
Time Frame
Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9
Title
Young Mania Rating Scale (YMRS) Scores
Description
The Young Mania Rating Scale is an eleven item interviewer-rated instrument. Four items are scored 0-8, the others 0-4. The total score therefore ranges from 0-60, with higher values reflecting greater severity.
Time Frame
Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of DSM-IV Bipolar Disorder, Type I: current manic, mixed, or hypomanic episodes Exclusion Criteria: Rapid cycling bipolar disorder History of substance abuse or dependence within last 3 months Diagnosis of schizophrenia or other chronic psychotic conditions Acute or unstable medical illness Documented intolerance to Lithium, Depakote, Risperidone, or Lorazepam Dementia Inability to communicate in English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Young, MD
Organizational Affiliation
Cornell University
Official's Role
Study Chair
Facility Information:
Facility Name
Precise Research Centers
City
Flowood
State/Province
Mississippi
ZIP/Postal Code
39232
Country
United States
Facility Name
Weill Cornell Medical College
City
White Plains
State/Province
New York
ZIP/Postal Code
10605
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
University Hospitals Case Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Centre for Addiction and Mental Health
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6J1H4
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
22467848
Citation
Al Jurdi RK, Schulberg HC, Greenberg RL, Kunik ME, Gildengers A, Sajatovic M, Mulsant BH, Young RC; GERI-BD Study Group. Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder. J Geriatr Psychiatry Neurol. 2012 Mar;25(1):62-8. doi: 10.1177/0891988712436684.
Results Reference
result
PubMed Identifier
24664811
Citation
Beyer JL, Greenberg RL, Marino P, Bruce ML, Al Jurdi RK, Sajatovic M, Gyulai L, Mulsant BH, Gildengers A, Young RC. Social support in late life mania: GERI-BD. Int J Geriatr Psychiatry. 2014 Oct;29(10):1028-32. doi: 10.1002/gps.4093. Epub 2014 Mar 24.
Results Reference
result
PubMed Identifier
21360754
Citation
Sajatovic M, Al Jurdi R, Gildengers A, Greenberg RL, Tenhave T, Bruce ML, Mulsant B, Young RC. Depression symptom ratings in geriatric patients with bipolar mania. Int J Geriatr Psychiatry. 2011 Nov;26(11):1201-8. doi: 10.1002/gps.2664. Epub 2011 Mar 1.
Results Reference
result
PubMed Identifier
21176032
Citation
Gildengers AG, Mulsant BH, Al Jurdi RK, Beyer JL, Greenberg RL, Gyulai L, Moberg PJ, Sajatovic M, ten Have T, Young RC; GERI-BD Study Group. The relationship of bipolar disorder lifetime duration and vascular burden to cognition in older adults. Bipolar Disord. 2010 Dec;12(8):851-8. doi: 10.1111/j.1399-5618.2010.00877.x.
Results Reference
result
PubMed Identifier
20148867
Citation
Young RC, Schulberg HC, Gildengers AG, Sajatovic M, Mulsant BH, Gyulai L, Beyer J, Marangell L, Kunik M, Ten Have T, Bruce ML, Gur R, Marino P, Evans JD, Reynolds CF 3rd, Alexopoulos GS. Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. Bipolar Disord. 2010 Feb;12(1):56-67. doi: 10.1111/j.1399-5618.2009.00779.x.
Results Reference
result
PubMed Identifier
29088928
Citation
Young RC, Mulsant BH, Sajatovic M, Gildengers AG, Gyulai L, Al Jurdi RK, Beyer J, Evans J, Banerjee S, Greenberg R, Marino P, Kunik ME, Chen P, Barrett M, Schulberg HC, Bruce ML, Reynolds CF 3rd, Alexopoulos GS; GERI-BD Study Group. GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Am J Psychiatry. 2017 Nov 1;174(11):1086-1093. doi: 10.1176/appi.ajp.2017.15050657. Epub 2017 Aug 4.
Results Reference
derived

Learn more about this trial

Treatment of Bipolar Mania in Older Adults

We'll reach out to this number within 24 hrs